Form 4: Century Therapeutics Director Daphne Quimi Granted 44,000 Stock Options

Century Therapeutics, Inc. Director Daphne Quimi was granted 44,000 stock options with an exercise price of $0.6 per share, vesting over approximately one year.

Summary

• Daphne Quimi, a Director of Century Therapeutics, Inc. (IPSC), was granted 44,000 stock options.
• The transaction date for this grant was June 12, 2025.
• Each stock option has an exercise price of $0.6.
• The options are set to expire on June 12, 2035.
• Vesting for these options will occur on the earlier of June 12, 2026, or the next annual meeting of stockholders, contingent upon Ms. Quimi's continued service.
• Following this transaction, Ms. Quimi beneficially owns 44,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (stock option grant) for a director, which is generally neutral but can be seen as slightly positive due to interest alignment.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued service and commitment to the company.

Risks

• The value of the stock options is dependent on the future market price of Century Therapeutics, Inc. common stock, which may fluctuate.
• The options are subject to a vesting schedule, meaning they are not immediately exercisable and require continued service.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of continued service from Director Daphne Quimi through at least June 12, 2026, or the next annual meeting of stockholders.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to directors is a standard compensation mechanism across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While the specific size and exercise price of this grant are unique to Century Therapeutics, the general structure aligns with typical equity compensation plans for non-employee directors.
• The document does not provide specific comparable companies or projects to benchmark the grant size against, but it is consistent with general industry practices for director equity incentives.

Corporate Governance

Related Party Transactions

• The grant of 44,000 stock options to Director Daphne Quimi constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the next annual meeting of stockholders, subject to continued service.
• Upon vesting, the director will have the right to exercise the options to purchase common stock at the specified exercise price.

Key Dates

Keywords

Century Therapeutics, IPSC, Stock Option, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction, Biotechnology, Pharmaceuticals